Sirolimus
Formula: C51H79NO13 (913.5551)
Chinese Name: 雷帕霉素(DMSO溶液), 雷帕霉素
BioDeep ID: BioDeep_00000230911
( View LC/MS Profile)
SMILES: [H][C@@]12CC[C@@H](C)[C@@](O)(O1)C(=O)C(=O)N1CCCC[C@@]1([H])C(=O)O[C@@]([H])(CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C2)OC)[C@H](C)C[C@@H]1CC[C@@H](O)[C@@H](C1)OC
Found 44 Sample Hits
m/z | Adducts | Species | Organ | Scanning | Sample | |
---|---|---|---|---|---|---|
896.5638 | [M+H-H2O]+PPM:13.4 |
Mus musculus | Urinary bladder | MALDI (CHCA) |
HR2MSI_mouse_urinary_bladder - S096 - PXD001283Resolution: 10μm, 260x134
Mass spectrometry imaging of phospholipids in mouse urinary bladder (imzML dataset) |
|
878.5315 | [M+H-2H2O]+PPM:11.1 |
Mus musculus | Lung | MALDI (DHB) |
image3 - MTBLS2075Resolution: 40μm, 146x190
Fig. 4 MALDI-MSI data of mouse lung tissue after administration with D9-choline and U13C-DPPC–containing Poractant alfa surfactant (labels administered 12 h prior to tissue collection). Ion images of (A) m/z 796.6856 ([U13C-DPPC+Na]+), (B) m/z 756.5154 [PC32:0+Na]+), and (C) m/z 765.6079 ([D9-PC32:0+Na]+). D: Overlay image of [U13C-PC32:0+Na]+ (red) and [D9-PC32:0+Na]+ (green). Part-per-million (ppm) mass errors are indicated in parentheses. All images were visualized using total-ion-current normalization and using hotspot removal (high quantile = 99%). DPPC = PC16:0/16:0. MSI, mass spectrometry imaging; PC, phosphatidylcholine; U13C-DPPC, universally 13C-labeled dipalmitoyl PC. |
|
878.5288 | [M+H-2H2O]+PPM:14.2 |
Mus musculus | Lung | MALDI (DHB) |
image4 - MTBLS2075Resolution: 40μm, 162x156
Fig 6c
Fig. 6 MALDI-MSI of U13C-PC16:0/16:0 acyl chain remodeling. A: Averaged MALDI mass spectrum from lung tissue collected from mice euthanized 12 h after administration of D9-choline and U13C-DPPC–containing Poractant alfa surfactant. The ion at m/z 828.6321 is assigned as the [M+Na]+ ion of 13C24-PC16:0_20:4 formed by acyl remodeling of U13C-PC16:0/16:0. The “NL” value refers to the intensity of the base peak in the full range MS1 spectrum. B: MS/MS spectrum of precursor ions at m/z 828.5 ± 0.5 with fragment ions originating from [13C24-PC16:0_20:4+Na]+ annotated. Part-per-million (ppm) mass errors are provided in parentheses. C, D: MALDI-MSI data of [U13C-DPPC+Na]+ (blue), [PC36:4+Na]+ (green) and [13C24-PC16:0_20:4+Na]+ (red) in lung tissue collected from mice (C) 12 h and (D) 18 h after label administration. All images were visualized using total-ion-current normalization and hotspot removal (high quantile = 99%). MS/MS, tandem mass spectrometry; MSI, mass spectrometry imaging; PC, phosphatidylcholine; U13C-DPPC, universally 13C-labeled dipalmitoyl PC. |
|
878.5332 | [M+H-2H2O]+PPM:9.2 |
Homo sapiens | esophagus | DESI () |
LNTO22_1_3 - MTBLS385Resolution: 75μm, 121x68
|
|
913.5845 | [M-H2O+NH4]+PPM:6.7 |
Homo sapiens | esophagus | DESI () |
LNTO22_1_3 - MTBLS385Resolution: 75μm, 121x68
|
|
878.5294 | [M+H-2H2O]+PPM:13.5 |
Homo sapiens | esophagus | DESI () |
LNTO22_1_4 - MTBLS385Resolution: 17μm, 82x80
|
|
913.5797 | [M-H2O+NH4]+PPM:1.5 |
Homo sapiens | esophagus | DESI () |
LNTO22_1_4 - MTBLS385Resolution: 17μm, 82x80
|
|
878.5309 | [M+H-2H2O]+PPM:11.8 |
Rattus norvegicus | Brain | MALDI (CHCA) |
2018June2820180628_brain_POS_3s2_validated - MTBLS3154Resolution: 17μm, 213x141
All MSI experiments were performed on a hybrid linear ion trap 21 T FT-ICR mass spectrometer at the National High Magnetic Field Laboratory (NHMFL) at Florida State University (Tallahassee, FL). A Velos Pro linear ion trap (Thermo Scientific, San Jose, CA) was combined with NHMFL-designed external linear quadrupole ion trap, quadrupole ion transfer optics and a novel dynamically harmonized ICR cell, which is operated at 7.5 V trapping potential[1]. Briefly, the cell uses 120° cell segments for ion excitation and detection, for improved excitation electric field, detection sensitivity and reduced third harmonic signals[2][3].
The commercial ion source and stacked ring ion guide were replaced with an elevated-pressure MALDI ion source incorporating a dual-ion funnel interface (Spectroglyph LLC, Kennewick, WA) as has been described previously[4]. Voltages within the funnels were 625 kHz, 150 V peak-to-peak (first, high-pressure ion funnel) and 1.2 MHz, 90 V peak-to-peak (second, low-pressure ion funnel). An electric field gradient of ∼10 V/cm was maintained within the dual-funnel system, with a gradient of 100 V/cm between the sample and the funnel inlet. The system was equipped with a Q-switched, frequency-tripled Nd:YLF laser emitting 349 nm light (Explorer One, Spectra Physics, Mountain View, CA). The laser was operated at a repetition rate of 1 kHz and pulse energy of ∼1.2 μJ. Pressure within the ion source was set to 10 mbar in the first ion funnel and 2 mbar in the second ion funnel. MALDI stage motion was synchronized with ion accumulation using the Velos trigger signal indicating commencement of the ion trap injection event, as previously described[4]. The mass spectrometer was operated with an ion injection time of 250 ms and automatic gain control (AGC) was turned off. A transient duration of 3.1 s was used for ultrahigh mass resolving power analyses, resulting in a total time of 4s per pixel. Spectra were obtained in both positive and negative mode, at 100 μm spatial resolution. Total number of pixels per brain section were approximately 22 000 and 24 h of experimental time. A Predator data station was used for ion excitation and detection[5].
Refs:
[1] Hendrickson CL, Quinn JP, Kaiser NK, Smith DF, Blakney GT, Chen T, Marshall AG, Weisbrod CR, Beu SC. 21 Tesla Fourier Transform Ion Cyclotron Resonance Mass Spectrometer: A National Resource for Ultrahigh Resolution Mass Analysis. J Am Soc Mass Spectrom. 2015 Sep;26(9):1626-32. doi:10.1007/s13361-015-1182-2. Epub 2015 Jun 20. PMID:26091892.
[2] Hendrickson CL, Beu SC, Blakney GT, Kaiser NK, McIntosh DG, Quinn JP, Marshall AG. In Optimized cell geometry for Fourier transform ion cyclotron resonance mass spectrometry, Proceedings of the 57th ASMS Conference on Mass Spectrometry and Allied Topics, Philadelphia, PA, May 31 to June 4; Philadelphia, PA, 2009.
[3] Chen T, Beu SC, Kaiser NK, Hendrickson CL. Note: Optimized circuit for excitation and detection with one pair of electrodes for improved Fourier transform ion cyclotron resonance mass spectrometry. Rev Sci Instrum. 2014 Jun;85(6):066107. doi:10.1063/1.4883179. PMID:24985871.
[4] Belov ME, Ellis SR, Dilillo M, Paine MRL, Danielson WF, Anderson GA, de Graaf EL, Eijkel GB, Heeren RMA, McDonnell LA. Design and Performance of a Novel Interface for Combined Matrix-Assisted Laser Desorption Ionization at Elevated Pressure and Electrospray Ionization with Orbitrap Mass Spectrometry. Anal Chem. 2017 Jul 18;89(14):7493-7501. doi:10.1021/acs.analchem.7b01168. Epub 2017 Jun 28. PMID:28613836.
[5] Blakney GT, Hendrickson CL, Marshall AG. Predator data station: A fast data acquisition system for advanced FT-ICR MS experiments. Int. J. Mass Spectrom. 2011;306 (2-3), 246- 252. doi:10.1016/j.ijms.2011.03.009. |
|
896.5414 | [M+H-H2O]+PPM:11.6 |
Rattus norvegicus | Brain | MALDI (CHCA) |
2018June2820180628_brain_POS_3s2_validated - MTBLS3154Resolution: 17μm, 213x141
All MSI experiments were performed on a hybrid linear ion trap 21 T FT-ICR mass spectrometer at the National High Magnetic Field Laboratory (NHMFL) at Florida State University (Tallahassee, FL). A Velos Pro linear ion trap (Thermo Scientific, San Jose, CA) was combined with NHMFL-designed external linear quadrupole ion trap, quadrupole ion transfer optics and a novel dynamically harmonized ICR cell, which is operated at 7.5 V trapping potential[1]. Briefly, the cell uses 120° cell segments for ion excitation and detection, for improved excitation electric field, detection sensitivity and reduced third harmonic signals[2][3].
The commercial ion source and stacked ring ion guide were replaced with an elevated-pressure MALDI ion source incorporating a dual-ion funnel interface (Spectroglyph LLC, Kennewick, WA) as has been described previously[4]. Voltages within the funnels were 625 kHz, 150 V peak-to-peak (first, high-pressure ion funnel) and 1.2 MHz, 90 V peak-to-peak (second, low-pressure ion funnel). An electric field gradient of ∼10 V/cm was maintained within the dual-funnel system, with a gradient of 100 V/cm between the sample and the funnel inlet. The system was equipped with a Q-switched, frequency-tripled Nd:YLF laser emitting 349 nm light (Explorer One, Spectra Physics, Mountain View, CA). The laser was operated at a repetition rate of 1 kHz and pulse energy of ∼1.2 μJ. Pressure within the ion source was set to 10 mbar in the first ion funnel and 2 mbar in the second ion funnel. MALDI stage motion was synchronized with ion accumulation using the Velos trigger signal indicating commencement of the ion trap injection event, as previously described[4]. The mass spectrometer was operated with an ion injection time of 250 ms and automatic gain control (AGC) was turned off. A transient duration of 3.1 s was used for ultrahigh mass resolving power analyses, resulting in a total time of 4s per pixel. Spectra were obtained in both positive and negative mode, at 100 μm spatial resolution. Total number of pixels per brain section were approximately 22 000 and 24 h of experimental time. A Predator data station was used for ion excitation and detection[5].
Refs:
[1] Hendrickson CL, Quinn JP, Kaiser NK, Smith DF, Blakney GT, Chen T, Marshall AG, Weisbrod CR, Beu SC. 21 Tesla Fourier Transform Ion Cyclotron Resonance Mass Spectrometer: A National Resource for Ultrahigh Resolution Mass Analysis. J Am Soc Mass Spectrom. 2015 Sep;26(9):1626-32. doi:10.1007/s13361-015-1182-2. Epub 2015 Jun 20. PMID:26091892.
[2] Hendrickson CL, Beu SC, Blakney GT, Kaiser NK, McIntosh DG, Quinn JP, Marshall AG. In Optimized cell geometry for Fourier transform ion cyclotron resonance mass spectrometry, Proceedings of the 57th ASMS Conference on Mass Spectrometry and Allied Topics, Philadelphia, PA, May 31 to June 4; Philadelphia, PA, 2009.
[3] Chen T, Beu SC, Kaiser NK, Hendrickson CL. Note: Optimized circuit for excitation and detection with one pair of electrodes for improved Fourier transform ion cyclotron resonance mass spectrometry. Rev Sci Instrum. 2014 Jun;85(6):066107. doi:10.1063/1.4883179. PMID:24985871.
[4] Belov ME, Ellis SR, Dilillo M, Paine MRL, Danielson WF, Anderson GA, de Graaf EL, Eijkel GB, Heeren RMA, McDonnell LA. Design and Performance of a Novel Interface for Combined Matrix-Assisted Laser Desorption Ionization at Elevated Pressure and Electrospray Ionization with Orbitrap Mass Spectrometry. Anal Chem. 2017 Jul 18;89(14):7493-7501. doi:10.1021/acs.analchem.7b01168. Epub 2017 Jun 28. PMID:28613836.
[5] Blakney GT, Hendrickson CL, Marshall AG. Predator data station: A fast data acquisition system for advanced FT-ICR MS experiments. Int. J. Mass Spectrom. 2011;306 (2-3), 246- 252. doi:10.1016/j.ijms.2011.03.009. |
|
936.5364 | [M+Na]+PPM:8.5 |
Rattus norvegicus | Brain | MALDI (CHCA) |
2018June2820180628_brain_POS_3s2_validated - MTBLS3154Resolution: 17μm, 213x141
All MSI experiments were performed on a hybrid linear ion trap 21 T FT-ICR mass spectrometer at the National High Magnetic Field Laboratory (NHMFL) at Florida State University (Tallahassee, FL). A Velos Pro linear ion trap (Thermo Scientific, San Jose, CA) was combined with NHMFL-designed external linear quadrupole ion trap, quadrupole ion transfer optics and a novel dynamically harmonized ICR cell, which is operated at 7.5 V trapping potential[1]. Briefly, the cell uses 120° cell segments for ion excitation and detection, for improved excitation electric field, detection sensitivity and reduced third harmonic signals[2][3].
The commercial ion source and stacked ring ion guide were replaced with an elevated-pressure MALDI ion source incorporating a dual-ion funnel interface (Spectroglyph LLC, Kennewick, WA) as has been described previously[4]. Voltages within the funnels were 625 kHz, 150 V peak-to-peak (first, high-pressure ion funnel) and 1.2 MHz, 90 V peak-to-peak (second, low-pressure ion funnel). An electric field gradient of ∼10 V/cm was maintained within the dual-funnel system, with a gradient of 100 V/cm between the sample and the funnel inlet. The system was equipped with a Q-switched, frequency-tripled Nd:YLF laser emitting 349 nm light (Explorer One, Spectra Physics, Mountain View, CA). The laser was operated at a repetition rate of 1 kHz and pulse energy of ∼1.2 μJ. Pressure within the ion source was set to 10 mbar in the first ion funnel and 2 mbar in the second ion funnel. MALDI stage motion was synchronized with ion accumulation using the Velos trigger signal indicating commencement of the ion trap injection event, as previously described[4]. The mass spectrometer was operated with an ion injection time of 250 ms and automatic gain control (AGC) was turned off. A transient duration of 3.1 s was used for ultrahigh mass resolving power analyses, resulting in a total time of 4s per pixel. Spectra were obtained in both positive and negative mode, at 100 μm spatial resolution. Total number of pixels per brain section were approximately 22 000 and 24 h of experimental time. A Predator data station was used for ion excitation and detection[5].
Refs:
[1] Hendrickson CL, Quinn JP, Kaiser NK, Smith DF, Blakney GT, Chen T, Marshall AG, Weisbrod CR, Beu SC. 21 Tesla Fourier Transform Ion Cyclotron Resonance Mass Spectrometer: A National Resource for Ultrahigh Resolution Mass Analysis. J Am Soc Mass Spectrom. 2015 Sep;26(9):1626-32. doi:10.1007/s13361-015-1182-2. Epub 2015 Jun 20. PMID:26091892.
[2] Hendrickson CL, Beu SC, Blakney GT, Kaiser NK, McIntosh DG, Quinn JP, Marshall AG. In Optimized cell geometry for Fourier transform ion cyclotron resonance mass spectrometry, Proceedings of the 57th ASMS Conference on Mass Spectrometry and Allied Topics, Philadelphia, PA, May 31 to June 4; Philadelphia, PA, 2009.
[3] Chen T, Beu SC, Kaiser NK, Hendrickson CL. Note: Optimized circuit for excitation and detection with one pair of electrodes for improved Fourier transform ion cyclotron resonance mass spectrometry. Rev Sci Instrum. 2014 Jun;85(6):066107. doi:10.1063/1.4883179. PMID:24985871.
[4] Belov ME, Ellis SR, Dilillo M, Paine MRL, Danielson WF, Anderson GA, de Graaf EL, Eijkel GB, Heeren RMA, McDonnell LA. Design and Performance of a Novel Interface for Combined Matrix-Assisted Laser Desorption Ionization at Elevated Pressure and Electrospray Ionization with Orbitrap Mass Spectrometry. Anal Chem. 2017 Jul 18;89(14):7493-7501. doi:10.1021/acs.analchem.7b01168. Epub 2017 Jun 28. PMID:28613836.
[5] Blakney GT, Hendrickson CL, Marshall AG. Predator data station: A fast data acquisition system for advanced FT-ICR MS experiments. Int. J. Mass Spectrom. 2011;306 (2-3), 246- 252. doi:10.1016/j.ijms.2011.03.009. |
|
913.5816 | [M-H2O+NH4]+PPM:3.5 |
Homo sapiens | esophagus | DESI () |
TO42T - MTBLS385Resolution: 17μm, 69x81
|
|
913.5831 | [M-H2O+NH4]+PPM:5.2 |
Homo sapiens | esophagus | DESI () |
LNTO30_8M_1 - MTBLS385Resolution: 17μm, 69x54
|
|
913.5814 | [M-H2O+NH4]+PPM:3.3 |
Homo sapiens | esophagus | DESI () |
TO39T - MTBLS385Resolution: 17μm, 69x81
|
|
913.5812 | [M-H2O+NH4]+PPM:3.1 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
80TopL, 50TopR, 70BottomL, 60BottomR-profile - MTBLS415Resolution: 17μm, 137x136
The human colorectal adenocarcinoma sample was excised during a surgical operation performed at the Imperial College Healthcare NHS Trust. The sample and procedures were carried out in accordance with ethical approval (14/EE/0024). |
|
914.5756 | [M+H]+PPM:14.4 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
80TopL, 50TopR, 70BottomL, 60BottomR-profile - MTBLS415Resolution: 17μm, 137x136
The human colorectal adenocarcinoma sample was excised during a surgical operation performed at the Imperial College Healthcare NHS Trust. The sample and procedures were carried out in accordance with ethical approval (14/EE/0024). |
|
914.5545 | [M+H]+PPM:8.6 |
Mytilus edulis | mantle | MALDI (DHB) |
20190201_MS38_Crassostrea_Mantle_350-1500_DHB_pos_A28_10um_270x210 - MTBLS2960Resolution: 10μm, 270x210
|
|
931.5901 | [M+NH4]+PPM:1.2 |
Mytilus edulis | mantle | MALDI (DHB) |
20190201_MS38_Crassostrea_Mantle_350-1500_DHB_pos_A28_10um_270x210 - MTBLS2960Resolution: 10μm, 270x210
|
|
914.5546 | [M+H]+PPM:8.5 |
Mytilus edulis | mantle | MALDI (DHB) |
20190216_MS38_Mytilus_mantle_350-1500_DHB_pos_A26_10um_275x210 - MTBLS2960Resolution: 10μm, 275x210
|
|
931.5895 | [M+NH4]+PPM:0.6 |
Mytilus edulis | mantle | MALDI (DHB) |
20190216_MS38_Mytilus_mantle_350-1500_DHB_pos_A26_10um_275x210 - MTBLS2960Resolution: 10μm, 275x210
|
|
913.5847 | [M-H2O+NH4]+PPM:6.9 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
520TopL, 490TopR, 510BottomL, 500BottomR-profile - MTBLS415Resolution: 17μm, 147x131
The human colorectal adenocarcinoma sample was excised during a surgical operation performed at the Imperial College Healthcare NHS Trust. The sample and procedures were carried out in accordance with ethical approval (14/EE/0024). |
|
914.5806 | [M+H]+PPM:19.9 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
520TopL, 490TopR, 510BottomL, 500BottomR-profile - MTBLS415Resolution: 17μm, 147x131
The human colorectal adenocarcinoma sample was excised during a surgical operation performed at the Imperial College Healthcare NHS Trust. The sample and procedures were carried out in accordance with ethical approval (14/EE/0024). |
|
896.568 | [M+H-H2O]+PPM:18 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
439TopL, 409TopR, 429BottomL, 419BottomR-profile - MTBLS415Resolution: 17μm, 157x136
The human colorectal adenocarcinoma sample was excised during a surgical operation performed at the Imperial College Healthcare NHS Trust. The sample and procedures were carried out in accordance with ethical approval (14/EE/0024). |
|
913.5832 | [M-H2O+NH4]+PPM:5.3 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
439TopL, 409TopR, 429BottomL, 419BottomR-profile - MTBLS415Resolution: 17μm, 157x136
The human colorectal adenocarcinoma sample was excised during a surgical operation performed at the Imperial College Healthcare NHS Trust. The sample and procedures were carried out in accordance with ethical approval (14/EE/0024). |
|
914.5793 | [M+H]+PPM:18.5 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
439TopL, 409TopR, 429BottomL, 419BottomR-profile - MTBLS415Resolution: 17μm, 157x136
The human colorectal adenocarcinoma sample was excised during a surgical operation performed at the Imperial College Healthcare NHS Trust. The sample and procedures were carried out in accordance with ethical approval (14/EE/0024). |
|
913.579 | [M-H2O+NH4]+PPM:0.7 |
Homo sapiens | NA | DESI () |
160TopL,130TopR,150BottomL,140BottomR-profile - MTBLS415Resolution: 17μm, 142x136
|
|
914.5797 | [M+H]+PPM:18.9 |
Homo sapiens | NA | DESI () |
160TopL,130TopR,150BottomL,140BottomR-profile - MTBLS415Resolution: 17μm, 142x136
|
|
913.581 | [M-H2O+NH4]+PPM:2.9 |
Homo sapiens | esophagus | DESI () |
TO40T - MTBLS385Resolution: 17μm, 82x74
|
|
913.5822 | [M-H2O+NH4]+PPM:4.2 |
Homo sapiens | esophagus | DESI () |
TO41T - MTBLS385Resolution: 75μm, 69x43
|
|
913.5846 | [M-H2O+NH4]+PPM:6.8 |
Homo sapiens | esophagus | DESI () |
LNTO22_1_7 - MTBLS385Resolution: 75μm, 69x54
|
|
931.5869 | [M+NH4]+PPM:2.2 |
Homo sapiens | esophagus | DESI () |
LNTO22_1_7 - MTBLS385Resolution: 75μm, 69x54
|
|
878.5485 | [M+H-2H2O]+PPM:8.2 |
Homo sapiens | esophagus | DESI () |
LNTO22_1_8 - MTBLS385Resolution: 75μm, 69x61
|
|
913.5841 | [M-H2O+NH4]+PPM:6.3 |
Homo sapiens | esophagus | DESI () |
LNTO22_1_8 - MTBLS385Resolution: 75μm, 69x61
|
|
931.5871 | [M+NH4]+PPM:2 |
Homo sapiens | esophagus | DESI () |
LNTO22_1_8 - MTBLS385Resolution: 75μm, 69x61
|
|
878.5319 | [M+H-2H2O]+PPM:10.7 |
Homo sapiens | esophagus | DESI () |
LNTO29_18_2 - MTBLS385Resolution: 75μm, 62x68
|
|
913.583 | [M-H2O+NH4]+PPM:5.1 |
Homo sapiens | esophagus | DESI () |
LNTO29_18_2 - MTBLS385Resolution: 75μm, 62x68
|
|
878.5324 | [M+H-2H2O]+PPM:10.1 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
240TopL, 210TopR, 230BottomL, 220BottomR-centroid - MTBLS176Resolution: 50μm, 142x141
|
|
913.5819 | [M-H2O+NH4]+PPM:3.9 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
240TopL, 210TopR, 230BottomL, 220BottomR-centroid - MTBLS176Resolution: 50μm, 142x141
|
|
931.5856 | [M+NH4]+PPM:3.6 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
240TopL, 210TopR, 230BottomL, 220BottomR-centroid - MTBLS176Resolution: 50μm, 142x141
|
|
878.5325 | [M+H-2H2O]+PPM:10 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
200TopL, 170TopR, 190BottomL, 180BottomR-centroid - MTBLS176Resolution: 50μm, 132x126
|
|
913.5826 | [M-H2O+NH4]+PPM:4.6 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
200TopL, 170TopR, 190BottomL, 180BottomR-centroid - MTBLS176Resolution: 50μm, 132x126
|
|
913.5817 | [M-H2O+NH4]+PPM:3.6 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
160TopL,130TopR,150BottomL,140BottomR-centroid - MTBLS176Resolution: 50μm, 142x136
|
|
878.5329 | [M+H-2H2O]+PPM:9.5 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
120TopL, 90TopR, 110BottomL, 100BottomR-centroid - MTBLS176Resolution: 50μm, 132x136
|
|
913.5826 | [M-H2O+NH4]+PPM:4.6 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
120TopL, 90TopR, 110BottomL, 100BottomR-centroid - MTBLS176Resolution: 50μm, 132x136
|
|
931.5851 | [M+NH4]+PPM:4.1 |
Homo sapiens | colorectal adenocarcinoma | DESI () |
120TopL, 90TopR, 110BottomL, 100BottomR-centroid - MTBLS176Resolution: 50μm, 132x136
|
|
Sirolimus is a macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent. It has a role as an immunosuppressive agent, an antineoplastic agent, an antibacterial drug, a mTOR inhibitor, a bacterial metabolite, an anticoronaviral agent and a geroprotector. It is a cyclic acetal, a cyclic ketone, an ether, a secondary alcohol, an organic heterotricyclic compound, an antibiotic antifungal drug and a macrolide lactam. Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex. Sirolimus is a mTOR Inhibitor Immunosuppressant and Kinase Inhibitor. The mechanism of action of sirolimus is as a mTOR Inhibitor and Protein Kinase Inhibitor. The physiologic effect of sirolimus is by means of Decreased Immunologic Activity. Sirolimus is macrocyclic antibiotic with potent immunosuppressive activity that is used alone or in combination with calcineurin inhibitors and corticosteroids to prevent cellular rejection after renal transplantation. Sirolimus therapy can be associated with mild serum enzyme elevations and it has been linked to rare instances of clinically apparent cholestatic liver injury. Sirolimus is a natural product found in Streptomyces rapamycinicus, Streptomyces hygroscopicus, and other organisms with data available. Sirolimus is a natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04) A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation ... Sirolimus is a macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to immunophilins. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties. [PubChem] A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EG - Mammalian target of rapamycin (mtor) kinase inhibitors L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials D000970 - Antineoplastic Agents > D000903 - Antibiotics, Antineoplastic > D020123 - Sirolimus C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2201 - mTOR Inhibitor D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C784 - Protein Synthesis Inhibitor > C261 - Macrolide Antibiotic D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C308 - Immunotherapeutic Agent > C574 - Immunosuppressant C254 - Anti-Infective Agent > C258 - Antibiotic S - Sensory organs > S01 - Ophthalmologicals Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2]. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2]. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].